Last reviewed · How we verify
DW4421S
DW4421S is a Small molecule drug developed by Daewon Pharmaceutical Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | DW4421S |
|---|---|
| Sponsor | Daewon Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunteers (PHASE1)
- A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DW4421S CI brief — competitive landscape report
- DW4421S updates RSS · CI watch RSS
- Daewon Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about DW4421S
What is DW4421S?
DW4421S is a Small molecule drug developed by Daewon Pharmaceutical Co., Ltd..
Who makes DW4421S?
DW4421S is developed by Daewon Pharmaceutical Co., Ltd. (see full Daewon Pharmaceutical Co., Ltd. pipeline at /company/daewon-pharmaceutical-co-ltd).
What development phase is DW4421S in?
DW4421S is in Phase 1.
Related
- Manufacturer: Daewon Pharmaceutical Co., Ltd. — full pipeline
- Compare: DW4421S vs similar drugs
- Pricing: DW4421S cost, discount & access